HealthcareLarge capRs 21,265 crRs 57.2 cr traded a day
Close on 2026-08-21
858.15
+1.97%
52-week range88% of the way up
511.40903.25
Market cap
21,265 cr
P/E (TTM)
32.1×
industry 44×
EPS (TTM)
26.73
Revenue YoY
+22.0%
Q1 FY27
Profit YoY
+59.8%
Net margin
12.2%
+2.9pt vs a year ago
Growth trend
-0.8pt
vs last quarter’s YoY
1 month
+0.7%
Below 52w high
5.3%
RSI (14)
55
Daily swing
2.9%
average true range
Volume
0.7×
vs 20-day average
Traded
Rs 57 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−0.03%
1 month
+0.66%
3 months
+13.44%
6 months
+45.20%
1 year
+68.99%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 0 against, 0 worth knowing
Supporting
trading 26% above its 200-day average
sitting at 88% of its 52-week range, with little overhead supply from trapped buyers
up 69% over twelve months
matches the market's strongest stocks, which has beaten the market by +0.37 points over 20 sessions across 48,607 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 22% year on year in the quarter ending 2026-06-30
net margin has widened from 10.1% to 12.2% across four quarters
priced at 32× earnings against an industry median of 44× — 27% below its peers
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
What would change this read: a close below 680, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +59.8% year on year, Rs 113 cr to Rs 180 cr.
+59.8%Rs 113 crRs 180 cr
Profit rose year on year in all 4 of the last 4 quarters.
4
Profit grew faster than revenue, +59.8% against +22.0%.
+59.8%+22.0%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
7 of 47 matched on 2026-08-21
GRANULES matches 7 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
GRANULES trades at 32× trailing earnings, above its median of 28× over this window — 15% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · M&A filings were typically +0.23pt vs the market over the next 5 sessions (n=981)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 22% against the same quarter a year earlier
profit rose 60% year on year
revenue rose in 4 of the last 4 quarters
Going against it
net margin narrowed from 13.7% to 12.2%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
1,477
240
180
7.26
12.2%
Q4 FY26
2026-03-31 · consolidated
1,471
262
202
8.23
13.7%
Q3 FY26
2025-12-31 · consolidated
1,388
202
150
6.19
10.8%
Q2 FY26
2025-09-30 · consolidated
1,297
176
131
5.38
10.1%
Q1 FY26
2025-06-30 · consolidated
1,210
145
113
4.64
9.3%
Q4 FY25
2025-03-31 · consolidated
1,197
198
152
6.27
12.7%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+2.6%
Versus 200-day average+26.2%
Below 52-week high-5.0%
Above 52-week low+67.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)54.8
Higher closes in last 53 of 5
Six-month return+45.20%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.89%
Volume versus 20-day0.7x
Median daily turnoverRs 57.2 cr
Peers
Healthcare · 67 classified companies
GRANULES trades at 32.1× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 27%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.